1. Alter MJ, Kruszon-Morgan D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556-562.

2. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(3 Suppl 1):62-65S.

3. EASL: International Consensus Conference on Hepatitis C Consensus Statement. J Hepatol. 1999;30:956-961.

4. Amarapurkar D. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol. 2000;15(Suppl E):105-110.

5. Lucidarme D, Dumas F, Arpurt JP, et al. Rapid progress of cirrhosis in hepatitis C: the role of age at the time of viral contamination. Presse Med. 1998;27(13):608-611.

6. Bortolotti F, Faggion S, Con P. Natural history of chronic viral hepatitis in childhood. Acta Gastroenterol Belg. 1998;61(2):198-201.

7. Datz C, Cramp M, Haas T, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 1999;44(4):563-567.

8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-832.

9. Kuboki M, Shinzawa H, Shao L, et al. A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Liver. 1999;19(2):88-96.

10. Alric L, Fort M, Izopet J, et al. Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens. 2000;56(2):154-158.

11. Inoue G, Horiike N, Michitaka K, Onji M. Hepatitis C virus clearance is prominent in women in an endemic area . J Gastroenterol Hepatol. 2000;15(9):1054-1058.

12. Yamakawa Y, Sata M, Suzuki H, Noguchi S, Tanikawa K. Higher elimination rate of hepatitis C virus among women. J Viral Hepat. 1996;3(6):317-321.

13. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol. 1999;31(Suppl 1):17-24.

14. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29(4):1215-1219.

15. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29(4):1215-1219.

16. Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26(3 Suppl 1):43-47S. de Medina M, Schiff ER. Hepatitis C: diagnostic assays. Semin Liver Dis. 1995;15(1):33-40.

17. Atrah HI, Ahmed MM. Hepatitis C virus seroconversion by a third generation ELISA screening test in blood donors. J Clin Path. 1996;49:254-255.

18. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology. 1983; 85(2):439-462.

19. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(Suppl 1):9-16.

20. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3 Suppl 1):21-28S.

21. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(3 Suppl 1):15-20S.

22. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med. 1998;339(21):1485-1492.

23. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis. 2003;7(1):149-161.

24. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.

25. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965.

26. Yuki N, Hayashi N, et al. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatology. 1997;25(2):439-444.

27. Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Reviews. 1996;2:219-228.

28. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992;327(27):1906-1911.

29. Koretz RL, Stone O, Mousa M, Gitnick GL. Non-A, non-B posttransfusion hepatitis - a decade later. Gastroenterology. 1985;88(5 Pt 1):1251-1254.

30. Takahashi M, Yamada G, Miyamoto R, et al. Natural course of chronic hepatitis C. Am J Gastroenterol. 1993;88(2):240-243.

31. National Institutes of Health Consensus Development Conference Panel. Statement: management of hepatitis C. Hepatology. 1997;26(Suppl 1):2-10S.

32. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23(6):1334-1340.

33. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(Suppl 1):34-38S.